We do, however, agree that serious reconsideration of the role of benzodiazepines for the treatment of anxiety disorders is warranted, particularly in light of evidence that they can be effective and well tolerated, and continue to be widely prescribed (1). A recent meta-analysis of studies examining the relative efficacy and tolerability of benzodiazepines and antidepressants for the treatment of anxiety disorders (2) did not demonstrate a significant efficacy advantage for either class of agents, although benzodiazepines tended to be better tolerated. However, the vast majority of studies examined in this analysis included the use of the older tricyclic agents rather than the now more commonly used SSRIs. But important questions about the use of benzodiazepines in practice remain to be conclusively addressed. Although anxious patients with remote histories of substance abuse or mild depressive symptoms can apparently be given benzodiazepines safely, it is also clear that these agents can be ineffective for or worsen depression (if used as monotherapy), or can be abused by patients with a substance abuse diathesis. Furthermore, some patients experience significant difficulties discontinuing these agents, and there is some evidence, although inconclusive, that they may hamper the efficacy of cognitive-behavioral therapy in some patients.